---

         T R O U B L E D   C O M P A N Y   R E P O R T E R

              Saturday, December 9, 2023, Vol. 27, No. 342

                            Headlines

PHASEBIO PHARMACEUTICALS: Incurs $524,009 Net Loss in September
REVITALID PHARMACEUTICAL: Incurs $311,808 Net Loss in October

                            *********

PHASEBIO PHARMACEUTICALS: Incurs $524,009 Net Loss in September
---------------------------------------------------------------
PhaseBio Pharmaceuticals, Inc. filed with the U.S. Securities and
Exchange Commission its monthly operating report for September.

The Debtor's statement of operations reflected a net loss of
$524,009 for September, a decrease from the $608,097 net loss
reported in August.

As of September 30, 2023, the Debtor listed $5.02 million in total
assets, $176.89 million in total liabilities, and -$171.87 million
in total shareholders' equity.

The Debtor started the month with $3.66 million cash. It listed
total disbursements of $394,542.  At month end, the Debtor had
$3.26 million cash.

A copy of the monthly operating report is available at the SEC at:

                   https://tinyurl.com/yr7f8y3s

             About PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. -- https://www.phasebio.com/ -- is
focused on the development and commercialization of novel therapies
to treat orphan diseases, with an initial focus on cardiopulmonary
indications. It is based in Malvern, Pa.

PhaseBio Pharmaceuticals filed a petition for relief under Chapter
11 of the Bankruptcy Code (Bankr. D. Del. Case No. 22-10995) on
Oct. 24, 2022. In the petition filed by its chief executive
officer, Jonathan Mow, the Debtor reported $17,970,000 in assets
and $21,320,000 in debt as of Aug. 31, 2022.

Judge Laurie Selber Silverstein oversees the case.

The Debtor tapped Cooley LLP as lead bankruptcy counsel; Richards,
Layton & Finger, PA as Delaware bankruptcy counsel;
SierraConstellation Partners, LLC as financial advisor; KPMG, LLP
as tax consultant; and Miller Buckfire & Co. as investment banker.
Omni Agent Solutions is the claims, noticing and administrative
agent.

The U.S. Trustee for Region 3 appointed an official committee of
unsecured creditors in the Debtor's case on Nov. 3, 2022. McDermott
Will & Emery, LLP and FTI Consulting, Inc., serve as the
committee's legal counsel and financial advisor, respectively.


REVITALID PHARMACEUTICAL: Incurs $311,808 Net Loss in October
-------------------------------------------------------------
RevitaLid Pharmaceutical Corp filed with the U.S. Securities and
Exchange Commission its monthly operating report for October 2023.

The Debtor's statement of operations reflected a net loss of
$311,808 for the current reporting period.

As of October 31, 2023, the Debtor listed $132.81 million in total
assets, $97.38 million in total liabilities, and $35.43 million in
total shareholders' equity.

The Debtor's operating report reflected zero receipts and
disbursements in October.

A copy of the monthly operating report is available at the SEC at:

                   https://tinyurl.com/ycxb66fm

                  About RevitaLid Pharmaceutical

RevitaLid Pharmaceutical Corp. is a specialty pharmaceutical
company focused on developing and commercializing eyecare and
medical aesthetics products.  The company is based in Bridgewater,
N.J.

RevitaLid Pharmaceutical Corp. and its affiliates filed Chapter 11
bankruptcy petitions (Bankr. D. Del. Lead Case No. 23-11704) on
Oct. 12, 2023, with $100 million to $500 million in both assets and
liabilities. Brian Markison, chief executive officer, signed the
petitions.

Judge Brendan Linehan Shannon oversees the cases.

The Debtors tapped Richards, Layton & Finger, PA and Ropes & Gray
LLP as legal counsel; Ernst & Young LLP as financial advisor; and
Ducera Partners LLC as their investment banker.  Kroll
Restructuring Administration LLC is the Debtors' administrative
advisor.



                            *********

Monday's edition of the TCR delivers a list of indicative prices
for bond issues that reportedly trade well below par.  Prices are
obtained by TCR editors from a variety of outside sources during
the prior week we think are reliable.  Those sources may not,
however, be complete or accurate.  The Monday Bond Pricing table
is compiled on the Friday prior to publication.  Prices reported
are not intended to reflect actual trades.  Prices for actual
trades are probably different.  Our objective is to share
information, not make markets in publicly traded securities.
Nothing in the TCR constitutes an offer or solicitation to buy or
sell any security of any kind.  It is likely that some entity
affiliated with a TCR editor holds some position in the issuers
public debt and equity securities about which we report.

Each Tuesday edition of the TCR contains a list of companies with
insolvent balance sheets whose shares trade higher than $3 per
share in public markets.  At first glance, this list may look like
the definitive compilation of stocks that are ideal to sell short.
Don't be fooled.  Assets, for example, reported at historical cost
net of depreciation may understate the true value of a firm's
assets.  A company may establish reserves on its balance sheet for
liabilities that may never materialize.  The prices at which
equity securities trade in public market are determined by more
than a balance sheet solvency test.

On Thursdays, the TCR delivers a list of recently filed
Chapter 11 cases involving less than $1,000,000 in assets and
liabilities delivered to nation's bankruptcy courts.  The list
includes links to freely downloadable images of these small-dollar
petitions in Acrobat PDF format.

Each Friday's edition of the TCR includes a review about a book of
interest to troubled company professionals.  All titles are
available at your local bookstore or through Amazon.com.  Go to
http://www.bankrupt.com/books/to order any title today.

Monthly Operating Reports are summarized in every Saturday edition
of the TCR.

The Sunday TCR delivers securitization rating news from the week
then-ending.

TCR subscribers have free access to our on-line news archive.
Point your Web browser to http://TCRresources.bankrupt.com/and use
the e-mail address to which your TCR is delivered to login.

                            *********

S U B S C R I P T I O N   I N F O R M A T I O N

Troubled Company Reporter is a daily newsletter co-published
by Bankruptcy Creditors Service, Inc., Fairless Hills,
Pennsylvania, USA, and Beard Group, Inc., Philadelphia, Pa., USA.
Randy Antoni, Jhonas Dampog, Marites Claro, Joy Agravante,
Rousel Elaine Tumanda, Joel Anthony G. Lopez, Psyche A. Castillon,
Ivy B. Magdadaro, Carlo Fernandez, Christopher G. Patalinghug, and
Peter A. Chapman, Editors.

Copyright 2023.  All rights reserved.  ISSN: 1520-9474.

This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic
re-mailing and photocopying) is strictly prohibited without prior
written permission of the publishers.  Information contained
herein is obtained from sources believed to be reliable, but is
not guaranteed.

The TCR subscription rate is $975 for 6 months delivered via
e-mail.  Additional e-mail subscriptions for members of the same
firm for the term of the initial subscription or balance thereof
are $25 each.  For subscription information, contact Peter A.
Chapman at 215-945-7000.

                   *** End of Transmission ***